Cargando…
Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111172/ https://www.ncbi.nlm.nih.gov/pubmed/35592470 http://dx.doi.org/10.3389/fneur.2022.837023 |
_version_ | 1784709243806416896 |
---|---|
author | Horisawa, Shiro Kohara, Kotaro Ebise, Hiroki Nishitani, Masahiko Kawamata, Takakazu Taira, Takaomi |
author_facet | Horisawa, Shiro Kohara, Kotaro Ebise, Hiroki Nishitani, Masahiko Kawamata, Takakazu Taira, Takaomi |
author_sort | Horisawa, Shiro |
collection | PubMed |
description | Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation. We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery. Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one). Single doses of zolpidem ranged between 2.5 and 10 mg, while daily dosages ranged from 10 to 30 mg. The zolpidem dose prescribed was 5–10 mg, with single and daily doses of 7 ± 2.9 and 14.5 ± 6.0 mg, respectively. With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.1 ± 6.7 to 3.7 ± 2.5 (50.6% improvement, p < 0.0001). Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively. No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale. Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2–3 h. Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively. Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited. |
format | Online Article Text |
id | pubmed-9111172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91111722022-05-18 Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study Horisawa, Shiro Kohara, Kotaro Ebise, Hiroki Nishitani, Masahiko Kawamata, Takakazu Taira, Takaomi Front Neurol Neurology Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation. We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery. Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one). Single doses of zolpidem ranged between 2.5 and 10 mg, while daily dosages ranged from 10 to 30 mg. The zolpidem dose prescribed was 5–10 mg, with single and daily doses of 7 ± 2.9 and 14.5 ± 6.0 mg, respectively. With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.1 ± 6.7 to 3.7 ± 2.5 (50.6% improvement, p < 0.0001). Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively. No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale. Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2–3 h. Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively. Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9111172/ /pubmed/35592470 http://dx.doi.org/10.3389/fneur.2022.837023 Text en Copyright © 2022 Horisawa, Kohara, Ebise, Nishitani, Kawamata and Taira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Horisawa, Shiro Kohara, Kotaro Ebise, Hiroki Nishitani, Masahiko Kawamata, Takakazu Taira, Takaomi Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study |
title | Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study |
title_full | Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study |
title_fullStr | Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study |
title_full_unstemmed | Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study |
title_short | Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study |
title_sort | efficacy and safety of zolpidem for focal dystonia after neurosurgical treatments: a retrospective cohort study |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111172/ https://www.ncbi.nlm.nih.gov/pubmed/35592470 http://dx.doi.org/10.3389/fneur.2022.837023 |
work_keys_str_mv | AT horisawashiro efficacyandsafetyofzolpidemforfocaldystoniaafterneurosurgicaltreatmentsaretrospectivecohortstudy AT koharakotaro efficacyandsafetyofzolpidemforfocaldystoniaafterneurosurgicaltreatmentsaretrospectivecohortstudy AT ebisehiroki efficacyandsafetyofzolpidemforfocaldystoniaafterneurosurgicaltreatmentsaretrospectivecohortstudy AT nishitanimasahiko efficacyandsafetyofzolpidemforfocaldystoniaafterneurosurgicaltreatmentsaretrospectivecohortstudy AT kawamatatakakazu efficacyandsafetyofzolpidemforfocaldystoniaafterneurosurgicaltreatmentsaretrospectivecohortstudy AT tairatakaomi efficacyandsafetyofzolpidemforfocaldystoniaafterneurosurgicaltreatmentsaretrospectivecohortstudy |